The Multiple Sclerosis Association of America Publishes 2014 MS Research Update

The Multiple Sclerosis Association of America (MSAA) is pleased to offer the latest MS Research Update, available as both a printed and online publication. This vital resource provides a comprehensive overview of research findings on the ten FDA-approved disease-modifying therapies for relapsing forms of multiple sclerosis (MS), as well as the latest study results on many experimental treatments currently under investigation. Directions for future research are also presented.

Included in this edition are updates on the currently approved drugs, such as the recently FDA-approved dosing option for Copaxone® and the FDA-labeling changes for Tysabri®. In addition to the exciting research aimed at relapsing forms of MS, a number of studies are now looking into the treatment of progressive forms of MS, which are highlighted in this edition of the MS Research Update for easy and quick identification. This update also features studies in areas such as stem-cell research, therapies for myelin repair and protection, biomarkers, genetic studies, and more.

Today, healthcare professionals and patients have numerous and more complex treatment options to consider. The need for patient education and awareness is crucial. This update and other MSAA resources are valuable tools for anyone looking for treatment information. Read or download the MS Research Update for free or order a printed copy at mymsaa.org.

For more information about MS and treatment options, please contact MSAA at (800) 532-7667, or visit mymsaa.org.